Ustekinumab (approximately 6 mg/kg) (DrugBank: Ustekinumab)
15 diseases告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
37 | 膿疱性乾癬(汎発型) | 0 |
41 | 巨細胞性動脈炎 | 0 |
46 | 悪性関節リウマチ | 0 |
49 | 全身性エリテマトーデス | 2 |
50 | 皮膚筋炎/多発性筋炎 | 0 |
53 | シェーグレン症候群 | 0 |
56 | ベーチェット病 | 0 |
65 | 原発性免疫不全症候群 | 0 |
84 | サルコイドーシス | 0 |
93 | 原発性胆汁性胆管炎[原発性胆汁性肝硬変 (~2017.3)] | 0 |
96 | クローン病 | 0 |
97 | 潰瘍性大腸炎 | 0 |
162 | 類天疱瘡(後天性表皮水疱症を含む。) | 0 |
269 | 化膿性無菌性関節炎・壊疽性膿皮症・アクネ症候群 | 0 |
271 | 強直性脊椎炎 | 0 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT04060888 (ClinicalTrials.gov) | July 14, 2020 | 16/8/2019 | A Study of Ustekinumab in Chinese Participants With Active Systemic Lupus Erythematosus | A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Ustekinumab in Chinese Subjects With Active Systemic Lupus Erythematosus | Lupus Erythematosus, Systemic | Drug: Ustekinumab (approximately 6 mg/kg);Drug: Ustekinumab 90 milligram (mg);Drug: Placebo | Janssen Research & Development, LLC | NULL | Withdrawn | 18 Years | 75 Years | All | 0 | Phase 3 | China |
2 | NCT03517722 (ClinicalTrials.gov) | April 16, 2018 | 13/4/2018 | A Study of Ustekinumab in Participants With Active Systemic Lupus Erythematosus | A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Ustekinumab in Subjects With Active Systemic Lupus Erythematosus | Lupus Erythematosus, Systemic | Drug: Placebo;Drug: Ustekinumab (approximately 6 mg/kg);Drug: Ustekinumab 90 mg | Janssen Research & Development, LLC | NULL | Active, not recruiting | 16 Years | 75 Years | All | 516 | Phase 3 | United States;Argentina;Bulgaria;Canada;China;Colombia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Ukraine;Australia;Ecuador;France;Peru;Philippines;Romania |